Drug profile

The FDA adverse-event record for Marbofloxacin

1,005 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Marbofloxacin. See the species affected, top reactions, and outcomes below.

1,005
adverse-event reports
13.7%
death-coded share
Dog
most-reported species
171
Vomiting - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
1,005
Total Reports
138
Deaths Reported
13.7%
Death Rate

Active Ingredients

Marbofloxacin

Administration Routes

OralUnknownSubcutaneous

Species Affected

Dog 686
Cat 299
Unknown 19
Human 1

Most Affected Breeds

Domestic Shorthair 146
Retriever - Labrador 70
Domestic (unspecified) 45
Crossbred Canine/dog 41
Dog (unknown) 31
Shih Tzu 31
Chihuahua 28
Shepherd Dog - German 23
Retriever - Golden 21
Pug 21

Most Reported Reactions

Vomiting 171
Anorexia 135
Lethargy (see also Central nervous system depression in 'Neurological') 135
Other abnormal test result NOS 98
Death by euthanasia 85
Lack of efficacy - NOS 75
Lack of efficacy (bacteria) - NOS 74
Weight loss 73
Ataxia 66
Anaemia NOS 65
Diarrhoea 63
Decreased appetite 58

Outcome Breakdown

Ongoing
382 (43.7%)
Outcome Unknown
200 (22.9%)
Recovered/Normal
145 (16.6%)
Euthanized
75 (8.6%)
Died
63 (7.2%)
Recovered with Sequela
9 (1.0%)

Marbofloxacin Adverse Event Insights

1,005 reports name Marbofloxacin; 138 recorded a death outcome (13.7% of reported events, not a population-level mortality rate). Active ingredient: Marbofloxacin. Administration routes: Oral, Unknown, Subcutaneous.

By species: Dog (686 reports), Cat (299 reports), Unknown (19 reports). By breed: Domestic Shorthair (146), Retriever - Labrador (70), Domestic (unspecified) (45).

Leading clinical signs: Vomiting (171), Anorexia (135), Lethargy (see also Central nervous system depression in 'Neurological') (135), Other abnormal test result NOS (98). Outcome, 874 coded reports: Ongoing leads at 43.7%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.